SG10202109752XA - Treatment of cancer using anti-cd19 chimeric antigen receptor - Google Patents

Treatment of cancer using anti-cd19 chimeric antigen receptor

Info

Publication number: SG10202109752XA
Authority: SG; Singapore
Prior art keywords: cancer; treatment; antigen receptor; chimeric antigen; chimeric
Prior art date: 2014-04-07

Application number

Other languages

English (en)

Inventor

Jennifer Brogdon

John Byrd

Jason Dubovsky

Joseph Fraietta

Saar Gill

David Glass

Amy Johnson

Carl June

Saad Kenderian

Joan Mannick

Marcela Maus

Leon Murphy

Natarajan Muthusamy

David L Porter

Marco Ruella

William Raj Sellers

Mariusz Wasik

Original Assignee

Novartis Ag

Univ Pennsylvania

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-04-07

Filing date

2015-04-07

Publication date

2021-10-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53008859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10202109752X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-04-07 Application filed by Novartis Ag, Univ Pennsylvania filed Critical Novartis Ag

2021-10-28 Publication of SG10202109752XA publication Critical patent/SG10202109752XA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001112—CD19 or B4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/36—Immune checkpoint inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/04—Immunosuppressors, e.g. cyclosporin, tacrolimus
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Hematology (AREA)
Oncology (AREA)
Mycology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Engineering & Computer Science (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

SG10202109752X 2014-04-07 2015-04-07 Treatment of cancer using anti-cd19 chimeric antigen receptor SG10202109752XA (en)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date
US201461976396P	2014-04-07	2014-04-07
US201462007309P	2014-06-03	2014-06-03
US201462036493P	2014-08-12	2014-08-12
US201462076238P	2014-11-06	2014-11-06
US201462087888P	2014-12-05	2014-12-05
US201462097278P	2014-12-29	2014-12-29

Publications (1)

Publication Number	Publication Date
SG10202109752XA true SG10202109752XA (en)	2021-10-28

Family

ID=53008859

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG11201606909RA SG11201606909RA (en)	2014-04-07	2015-04-07	Treatment of cancer using anti-cd19 chimeric antigen receptor
SG10202109752X SG10202109752XA (en)	2014-04-07	2015-04-07	Treatment of cancer using anti-cd19 chimeric antigen receptor

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SG11201606909RA SG11201606909RA (en)	2014-04-07	2015-04-07	Treatment of cancer using anti-cd19 chimeric antigen receptor

Country Status (24)

Country	Link
US (2)	US10357514B2 (ko)
EP (3)	EP3888674B1 (ko)
JP (3)	JP6765966B2 (ko)
KR (3)	KR20240042250A (ko)
CN (2)	CN107075482B (ko)
AU (3)	AU2015244039B2 (ko)
CA (1)	CA2940671A1 (ko)
DK (2)	DK3129470T3 (ko)
ES (2)	ES2876263T3 (ko)
FI (1)	FI3888674T3 (ko)
HR (2)	HRP20211055T1 (ko)
HU (2)	HUE066973T2 (ko)
IL (4)	IL293603B2 (ko)
LT (2)	LT3888674T (ko)
MX (2)	MX395149B (ko)
MY (1)	MY191608A (ko)
PL (2)	PL3129470T3 (ko)
PT (2)	PT3129470T (ko)
RU (1)	RU2718542C2 (ko)
SG (2)	SG11201606909RA (ko)
SI (2)	SI3129470T1 (ko)
TW (1)	TWI753848B (ko)
WO (1)	WO2015157252A1 (ko)
ZA (1)	ZA201605657B (ko)

Families Citing this family (211)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10155038B2 (en)	2007-02-02	2018-12-18	Yale University	Cells prepared by transient transfection and methods of use thereof
US9249423B2 (en)	2007-02-02	2016-02-02	Yale University	Method of de-differentiating and re-differentiating somatic cells using RNA
WO2010099205A1 (en) *	2009-02-24	2010-09-02	The Trustees Of The University Of Pennsylvania	Methods for treating progressive multifocal leukoencephalopathy (pml)
US11951140B2 (en)	2011-02-04	2024-04-09	Seed Health, Inc.	Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11951139B2 (en)	2015-11-30	2024-04-09	Seed Health, Inc.	Method and system for reducing the likelihood of osteoporosis
US11998479B2 (en)	2011-02-04	2024-06-04	Seed Health, Inc.	Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11844720B2 (en)	2011-02-04	2023-12-19	Seed Health, Inc.	Method and system to reduce the likelihood of dental caries and halitosis
US10940169B2 (en)	2015-11-30	2021-03-09	Joseph E. Kovarik	Method for reducing the likelihood of developing cancer in an individual human being
US12279989B2 (en)	2011-02-04	2025-04-22	Seed Health, Inc.	Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US12257272B2 (en)	2015-12-24	2025-03-25	Seed Health, Inc.	Method and system for reducing the likelihood of developing depression in an individual
EP4282419A1 (en)	2012-12-20	2023-11-29	Purdue Research Foundation	Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
ES2814962T3 (es)	2013-02-20	2021-03-29	Novartis Ag	Fijación eficaz como objetivo de la leucemia humana primaria utilizando células T modificadas con receptor de antígeno quimérico anti-CD123
KR102509562B1 (ko)	2013-02-20	2023-03-14	노파르티스 아게	인간화 항-EGFRvIII 키메라 항원 수용체를 사용한 암의 치료
US9745368B2 (en) *	2013-03-15	2017-08-29	The Trustees Of The University Of Pennsylvania	Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
TWI654206B (zh)	2013-03-16	2019-03-21	諾華公司	使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
CA3225453A1 (en)	2013-12-19	2015-06-25	Novartis Ag	Human mesothelin chimeric antigen receptors and uses thereof
US11213552B2 (en)	2015-11-30	2022-01-04	Joseph E. Kovarik	Method for treating an individual suffering from a chronic infectious disease and cancer
US11969445B2 (en)	2013-12-20	2024-04-30	Seed Health, Inc.	Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11980643B2 (en)	2013-12-20	2024-05-14	Seed Health, Inc.	Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US10287354B2 (en)	2013-12-20	2019-05-14	Novartis Ag	Regulatable chimeric antigen receptor
US11672835B2 (en)	2013-12-20	2023-06-13	Seed Health, Inc.	Method for treating individuals having cancer and who are receiving cancer immunotherapy
US11642382B2 (en)	2013-12-20	2023-05-09	Seed Health, Inc.	Method for treating an individual suffering from bladder cancer
US11833177B2 (en)	2013-12-20	2023-12-05	Seed Health, Inc.	Probiotic to enhance an individual's skin microbiome
US11529379B2 (en)	2013-12-20	2022-12-20	Seed Health, Inc.	Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
US11839632B2 (en)	2013-12-20	2023-12-12	Seed Health, Inc.	Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11998574B2 (en)	2013-12-20	2024-06-04	Seed Health, Inc.	Method and system for modulating an individual's skin microbiome
US12329783B2 (en)	2013-12-20	2025-06-17	Seed Health, Inc.	Method and system to improve the health of a person's skin microbiome
US12005085B2 (en)	2013-12-20	2024-06-11	Seed Health, Inc.	Probiotic method and composition for maintaining a healthy vaginal microbiome
US11026982B2 (en)	2015-11-30	2021-06-08	Joseph E. Kovarik	Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being
US12246043B2 (en)	2013-12-20	2025-03-11	Seed Health, Inc.	Topical application to treat acne vulgaris
US11826388B2 (en)	2013-12-20	2023-11-28	Seed Health, Inc.	Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
ES2963718T3 (es)	2014-01-21	2024-04-01	Novartis Ag	Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras
RU2718542C2 (ru) *	2014-04-07	2020-04-08	Новартис Аг	Лечение злокачественной опухоли с использованием химерного рецептора антигена против cd19
BR112016024072B1 (pt)	2014-04-16	2021-02-09	Juno Therapeutics Gmbh	método in vitro de estimular uma população de células
EP4450615A3 (en)	2014-04-23	2025-01-08	Juno Therapeutics, Inc.	Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
TWI719942B (zh)	2014-07-21	2021-03-01	瑞士商諾華公司	使用ｃｄ３３嵌合抗原受體治療癌症
TWI750110B (zh)	2014-07-21	2021-12-21	瑞士商諾華公司	使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
WO2016014553A1 (en)	2014-07-21	2016-01-28	Novartis Ag	Sortase synthesized chimeric antigen receptors
PL3183268T3 (pl)	2014-08-19	2020-09-07	Novartis Ag	Chimeryczny receptor antygenowy (CAR) anty-CD123 do zastosowania w leczeniu nowotworu złośliwego
PL3194443T3 (pl)	2014-09-17	2022-01-31	Novartis Ag	Nakierowywanie komórek cytotoksycznych za pośrednictwem receptorów chimerycznych do immunoterapii adoptywnej
CN106973568B (zh)	2014-10-08	2021-07-23	诺华股份有限公司	预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
WO2016064929A1 (en)	2014-10-20	2016-04-28	Juno Therapeutics, Inc.	Methods and compositions for dosing in adoptive cell therapy
WO2016098078A2 (en) *	2014-12-19	2016-06-23	Novartis Ag	Dimerization switches and uses thereof
IL253149B2 (en)	2014-12-29	2023-11-01	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells
WO2016115482A1 (en)	2015-01-16	2016-07-21	Novartis Pharma Ag	Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
WO2016126608A1 (en) *	2015-02-02	2016-08-11	Novartis Ag	Car-expressing cells against multiple tumor antigens and uses thereof
US20180140602A1 (en) *	2015-04-07	2018-05-24	Novartis Ag	Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
ES2923894T3 (es)	2015-04-08	2022-10-03	Novartis Ag	Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
AU2016249005B2 (en) *	2015-04-17	2022-06-16	Novartis Ag	Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
WO2016172583A1 (en)	2015-04-23	2016-10-27	Novartis Ag	Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
WO2016183041A2 (en)	2015-05-08	2016-11-17	President And Fellows Of Harvard College	Universal donor stem cells and related methods
AU2016297014B2 (en)	2015-07-21	2021-06-17	Novartis Ag	Methods for improving the efficacy and expansion of immune cells
EP3421590B1 (en)	2015-07-29	2021-07-14	ONK Therapeutics Limited	Modified natural killer cells and natural killer cell lines having increased cytotoxicity
US10906951B2 (en)	2015-07-29	2021-02-02	Onk Therapeutics Limited	Modified natural killer cells and natural killer cell lines having increased cytotoxicity
US11667691B2 (en)	2015-08-07	2023-06-06	Novartis Ag	Treatment of cancer using chimeric CD3 receptor proteins
US11747346B2 (en)	2015-09-03	2023-09-05	Novartis Ag	Biomarkers predictive of cytokine release syndrome
MA44909A (fr) *	2015-09-15	2018-07-25	Acerta Pharma Bv	Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
EP3660044A1 (en) *	2015-10-09	2020-06-03	Miltenyi Biotec Technology, Inc.	Chimeric antigen receptors and methods of use
AU2016337525B2 (en)	2015-10-16	2022-01-20	The Trustees Of Columbia University In The City Of New York	Compositions and methods for inhibition of lineage specific antigens
WO2017070092A1 (en)	2015-10-19	2017-04-27	University Of Massachusetts	Anti-cancer and anti-inflammatory therapeutics and methods thereof
HK1258932A1 (zh)	2015-10-22	2019-11-22	Juno Therapeutics Gmbh	用於轉導的方法、反應劑盒、反應劑和設備
SG10202107602XA (en)	2015-11-04	2021-08-30	Univ Pennsylvania	Methods and compositions for gene editing in hematopoietic stem cells
CA3006432A1 (en)	2015-12-04	2017-06-08	Novartis Ag	Compositions and methods for immunooncology
JP7082055B2 (ja)	2015-12-22	2022-06-07	ノバルティスアーゲー	抗癌治療における組み合わせ使用のためのメソテリンキメラ抗原受容体（ｃａｒ）およびｐｄ－ｌ１阻害剤に対する抗体
CN109153975A (zh)	2015-12-28	2019-01-04	诺华股份有限公司	制备嵌合抗原受体表达细胞的方法
ES2944597T3 (es)	2015-12-30	2023-06-22	Novartis Ag	Terapias con células efectoras inmunitarias de eficacia mejorada
EP3423482A1 (en) *	2016-03-04	2019-01-09	Novartis AG	Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
EP3432924A1 (en)	2016-03-23	2019-01-30	Novartis AG	Cell secreted minibodies and uses thereof
WO2017165869A1 (en) *	2016-03-25	2017-09-28	Trovagene, Inc.	Evaluaton of transgenes of genetically modified cells in bodily fluids
CN108778312B (zh) *	2016-04-08	2022-07-15	爱默蕾大学	使用基于细胞的疗法治疗癌症和传染病的方法
WO2017177149A2 (en)	2016-04-08	2017-10-12	Purdue Research Foundation	Methods and compositions for car t cell therapy
EP3443001B1 (en)	2016-04-11	2025-04-30	Obsidian Therapeutics, Inc.	REGULATED BIOCIRCUIT SYSTEMS
US10188749B2 (en)	2016-04-14	2019-01-29	Fred Hutchinson Cancer Research Center	Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
KR20180134385A (ko)	2016-04-15	2018-12-18	노파르티스 아게	선택적 단백질 발현을 위한 조성물 및 방법
US20210177896A1 (en)	2016-06-02	2021-06-17	Novartis Ag	Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
CA3026453A1 (en) *	2016-06-03	2017-12-07	Memorial Sloan-Kettering Cancer Center	Adoptive cell therapies as early treatment options
AU2017289270B2 (en) *	2016-06-27	2023-05-04	The Regents Of The University Of California	Cancer treatment combinations
CA3030837A1 (en) *	2016-07-15	2018-01-18	Novartis Ag	Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
KR20190034588A (ko)	2016-07-28	2019-04-02	노파르티스 아게	키메라 항원 수용체 및 pd-1 억제제의 조합 요법
KR20240153612A (ko)	2016-10-07	2024-10-23	노파르티스 아게	암의 치료를 위한 키메라 항원 수용체
SG10202104036QA (en) *	2016-10-28	2021-05-28	Morphosys Ag	Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
MA46783A (fr) *	2016-11-03	2019-09-11	Juno Therapeutics Inc	Polythérapie de type thérapie cellulaire t et inhibiteur de btk
AU2017363257B2 (en)	2016-11-22	2021-08-19	Dana-Farber Cancer Institute, Inc.	Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
JP7227131B2 (ja)	2016-12-03	2023-02-21	ジュノーセラピューティクスインコーポレイテッド	Ｃａｒ－ｔ細胞の投薬を決定するための方法
CN110545826A (zh)	2016-12-03	2019-12-06	朱诺治疗学股份有限公司	用于与激酶抑制剂组合使用治疗性t细胞的方法和组合物
MX2019006438A (es)	2016-12-05	2019-11-28	Juno Therapeutics Inc	Produccion de celulas modificadas para terapia de celulas adoptivas.
US20180100016A1 (en) *	2016-12-22	2018-04-12	Xiaotong Song	Use of car-modified human natural killer cells to treat cancer
JP7348063B2 (ja)	2017-01-05	2023-09-20	フレッドハッチンソンキャンサーセンター	ワクチン効力を改善するためのシステム及び方法
US11578115B2 (en)	2017-01-10	2023-02-14	The General Hospital Corporation	Chimeric antigen receptors based on alternative signal 1 domains
EP3574005B1 (en)	2017-01-26	2021-12-15	Novartis AG	Cd28 compositions and methods for chimeric antigen receptor therapy
WO2018148224A1 (en)	2017-02-07	2018-08-16	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
WO2018157171A2 (en)	2017-02-27	2018-08-30	Juno Therapeutics, Inc.	Compositions, articles of manufacture and methods related to dosing in cell therapy
WO2018160731A1 (en)	2017-02-28	2018-09-07	Novartis Ag	Shp inhibitor compositions and uses for chimeric antigen receptor therapy
US11850262B2 (en)	2017-02-28	2023-12-26	Purdue Research Foundation	Compositions and methods for CAR T cell therapy
US11352434B2 (en)	2017-03-16	2022-06-07	The General Hospital Corporation	Chimeric antigen receptors targeting CD37
US20200085871A1 (en) *	2017-03-17	2020-03-19	University Of Tennessee Research Foundation	Methods of using cytotoxic t cells for treatment of autoimmune diseases
CA3054621A1 (en)	2017-03-22	2018-09-27	Novartis Ag	Compositions and methods for immunooncology
IL269209B2 (en) *	2017-04-01	2023-11-01	Avm Biotechnology Llc	Replacement of cytotoxic preconditioning before cellular immunotherapy
AR111360A1 (es) *	2017-04-03	2019-07-03	Kite Pharma Inc	Tratamiento usando células t de receptor quimérico incorporando células t polifuncionales optimizadas
DK3618842T3 (da) *	2017-05-01	2024-01-02	Juno Therapeutics Inc	Kombination af en celleterapi og en immunomodulerende forbindelse
TW201904578A (zh) *	2017-05-10	2019-02-01	美商艾歐凡斯生物治療公司	源自液體腫瘤之腫瘤浸潤性淋巴細胞的擴增和該經擴增腫瘤浸潤性淋巴細胞之治療用途
WO2018209052A1 (en) *	2017-05-10	2018-11-15	Wellstat Immuno Therapeutics, Llc	Enveloped virus resistant to complement inactivation for the treatment of cancer
CA3065120A1 (en) *	2017-06-02	2018-12-06	Juno Therapeutics, Inc.	Articles of manufacture and methods for treatment using adoptive cell therapy
US11766442B2 (en)	2017-06-16	2023-09-26	City Of Hope	T-cell lymphoma treatments
EP3642240A1 (en)	2017-06-22	2020-04-29	Novartis AG	Antibody molecules to cd73 and uses thereof
WO2018237325A1 (en) *	2017-06-22	2018-12-27	University Of Southern California	Combination cancer therapy using chimeric antigen receptor engineered natural killer cells as chemotherapeutic drug carriers
CN110785187B (zh)	2017-06-22	2024-04-05	诺华股份有限公司	针对cd73的抗体分子及其用途
EP3655026A4 (en) *	2017-07-17	2021-07-28	Janssen Biotech, Inc.	ANTIGEN BINDING REGIONS DIRECTED TO FIELDS OF FIBRONECTIN TYPE III AND THEIR METHODS OF USE
CA3070579A1 (en)	2017-08-09	2019-02-14	Juno Therapeutics, Inc.	Methods for producing genetically engineered cell compositions and related compositions
CN109423481A (zh) *	2017-08-24	2019-03-05	上海恒润达生生物科技有限公司	一种cart细胞的放行检测方法
CN111936510B (zh) *	2017-09-15	2024-09-27	莱蒂恩技术公司	用于用抗cd19免疫治疗来治疗癌症的组合物和方法
US10927168B2 (en)	2017-10-02	2021-02-23	Humanicen, Inc.	Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
EP3691663A4 (en)	2017-10-02	2021-08-18	Humanigen, Inc.	METHODS OF TREATMENT OF TOXICITY ASSOCIATED WITH IMMUNOTHERAPIES USING A GM-CSF ANTAGONIST
US11130805B2 (en)	2017-10-02	2021-09-28	Humanigen, Inc.	Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
US10899831B2 (en)	2017-10-02	2021-01-26	Humanigen, Inc.	Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US11999802B2 (en)	2017-10-18	2024-06-04	Novartis Ag	Compositions and methods for selective protein degradation
EP3697435A1 (en) *	2017-10-20	2020-08-26	Fred Hutchinson Cancer Research Center	Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
WO2019084258A1 (en) *	2017-10-25	2019-05-02	Actinium Pharmaceuticals, Inc.	METHODS OF CONDITIONING BASED ON ANTI-CD45 AND USES THEREOF IN COMBINATION WITH GENETICALLY MODIFIED CELL THERAPIES
JP2021500894A (ja)	2017-10-25	2021-01-14	ノバルティスアーゲー	キメラ抗原受容体発現細胞を作製する方法
WO2019089798A1 (en)	2017-10-31	2019-05-09	Novartis Ag	Anti-car compositions and methods
AU2018360800B2 (en)	2017-11-01	2024-11-21	Juno Therapeutics, Inc.	Chimeric antigen receptors specific for B-cell maturation antigen (BCMA)
US11851679B2 (en)	2017-11-01	2023-12-26	Juno Therapeutics, Inc.	Method of assessing activity of recombinant antigen receptors
US11564946B2 (en)	2017-11-01	2023-01-31	Juno Therapeutics, Inc.	Methods associated with tumor burden for assessing response to a cell therapy
KR20200074997A (ko)	2017-11-01	2020-06-25	주노 쎄러퓨티크스 인코퍼레이티드	B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체
EP3703735A1 (en) *	2017-11-01	2020-09-09	Nantkwest, Inc.	Nk-92 cells to stimulate anti-cancer vaccine
WO2019089858A2 (en)	2017-11-01	2019-05-09	Juno Therapeutics, Inc.	Methods of assessing or monitoring a response to a cell therapy
JP7357626B2 (ja)	2017-11-01	2023-10-06	ジュノーセラピューティクスインコーポレイテッド	操作された細胞の治療用組成物を生成するためのプロセス
JP2021502829A (ja)	2017-11-14	2021-02-04	メモリアルスローンケタリングキャンサーセンター	Ｉｌ−３６を分泌する免疫応答性細胞およびその使用
KR20200088440A (ko) *	2017-11-21	2020-07-22	노파르티스 아게	종양-연관 항원에 대한 삼중특이성 결합 분자 및 이의 용도
CN111727373A (zh) *	2017-11-30	2020-09-29	诺华股份有限公司	靶向bcma的嵌合抗原受体及其用途
US12367978B2 (en)	2017-12-01	2025-07-22	Illumina, Inc.	Methods and systems for determining somatic mutation clonality
CN111989106A (zh) *	2017-12-01	2020-11-24	朱诺治疗学股份有限公司	基因工程化细胞的给药和调节方法
MX2020005906A (es)	2017-12-08	2020-10-22	Juno Therapeutics Inc	Marcadores fenotipicos para terapia celular y metodos relacionados.
EP3720874A1 (en) *	2017-12-08	2020-10-14	Juno Therapeutics, Inc.	Process for producing a composition of engineered t cells
EP3735255A4 (en) *	2018-01-05	2021-09-22	Maxcyte, Inc.	CHRONIC CANCER TREATMENT BY CARS
PT3737765T (pt) *	2018-01-12	2022-03-11	Curocell Inc	Células imunitárias melhoradas utilizando shrna duplo e composição incluindo as mesmas
EP3740217A4 (en)	2018-01-22	2021-11-10	Endocyte, Inc.	METHODS OF USE FOR T CAR LYMPHOCYTES
BR112020015884A2 (pt)	2018-02-06	2020-12-08	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Receptores de antígeno quimérico (cars) específicos de fluoresceína exibindo a função de célula t ótima contra os tumores marcados por fl-ple
EP3755366A4 (en)	2018-02-23	2021-12-29	Endocyte, Inc.	Sequencing method for car t cell therapy
US20200376035A1 (en) *	2018-02-26	2020-12-03	The Trustees Of The University Of Pennsylvania	Methods and compositions comprising cart and a smac mimetic
KR20230020023A (ko)	2018-03-14	2023-02-09	서피스 온콜로지, 인크.	Cd39에 결합하는 항체 및 이의 용도
AU2019247229A1 (en) *	2018-04-05	2020-10-15	Novartis Ag	Trispecific binding molecules against cancers and uses thereof
CA3104034A1 (en) *	2018-05-01	2019-11-07	Fred Hutchinson Cancer Research Center	Nanoparticles for gene expression and uses thereof
US20210213063A1 (en)	2018-05-25	2021-07-15	Novartis Ag	Combination therapy with chimeric antigen receptor (car) therapies
TWI869346B (zh)	2018-05-30	2025-01-11	瑞士商諾華公司	Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
WO2019232244A2 (en)	2018-05-31	2019-12-05	Novartis Ag	Antibody molecules to cd73 and uses thereof
US20210207095A1 (en) *	2018-06-01	2021-07-08	Monash University	Methods of activating cells via ptp 1b inhibition
WO2019241426A1 (en)	2018-06-13	2019-12-19	Novartis Ag	Bcma chimeric antigen receptors and uses thereof
AU2019290230A1 (en) *	2018-06-22	2020-12-03	The General Hospital Corporation	Chimeric antigen receptors targeting CD37 and CD19
CN108949695A (zh) *	2018-08-14	2018-12-07	杭州荣泽生物科技有限公司	一种非病毒载体共表达il18的car-t细胞构建及其应用
US20220364055A1 (en)	2018-08-31	2022-11-17	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells
EP3844265A2 (en)	2018-08-31	2021-07-07	Novartis AG	Methods of making chimeric antigen receptor-expressing cells
US20210338729A1 (en) *	2018-10-12	2021-11-04	Icell Gene Therapeutics Llc	CHIMERIC ANTIGEN RECEPTORS (CARs) COMPOSITIONS AND METHODS OF USE THEREOF
BR112021008263A2 (pt) *	2018-10-31	2021-08-10	Humanigen, Inc.	materiais e métodos para tratamento de câncer
EP3873500A4 (en)	2018-10-31	2023-01-11	Mayo Foundation for Medical Education and Research	CANCER TREATMENT METHODS AND MATERIALS
EP3873540A4 (en)	2018-10-31	2022-07-27	Mayo Foundation for Medical Education and Research	Methods and materials for treating cancer
JP2022512971A (ja)	2018-11-08	2022-02-07	ジュノーセラピューティクスインコーポレイテッド	処置およびｔ細胞調節のための方法および併用
WO2020172553A1 (en)	2019-02-22	2020-08-27	Novartis Ag	Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
KR20210134339A (ko)	2019-02-25	2021-11-09	노파르티스 아게	바이러스 전달을 위한 메조다공성 실리카 입자 조성물
US20220168389A1 (en)	2019-04-12	2022-06-02	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells
EP3959320A1 (en)	2019-04-24	2022-03-02	Novartis AG	Compositions and methods for selective protein degradation
BR112021021787A2 (pt) *	2019-04-30	2022-01-04	Memorial Sloan Kettering Cancer Center	Terapias de combinação
CN110157680A (zh) *	2019-05-08	2019-08-23	浙江大学	提高嵌合抗原受体t细胞疗效和作用持久性的细胞培养方法
JP7489407B2 (ja)	2019-05-21	2024-05-23	ノバルティスアーゲー	Ｃｄ１９結合分子及びその使用
CN110218702B (zh) *	2019-06-14	2024-02-27	博生吉医药科技(苏州)有限公司	靶向cd138和cd19的免疫细胞组合及其应用
JP7708436B2 (ja)	2019-08-30	2025-07-15	イェールユニバーシティー	核酸を細胞に送達するための組成物および方法
US20220348651A1 (en)	2019-09-18	2022-11-03	Novartis Ag	Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
CN114981413A (zh) *	2019-10-23	2022-08-30	昆士兰医学研究所理事会	过继免疫治疗
AU2020375149A1 (en) *	2019-10-31	2022-05-12	Incyte Corporation	Sequential anti-CD19 therapy
TW202440622A (zh) *	2019-11-06	2024-10-16	美商凱特製藥公司	嵌合抗原受體t細胞療法
AU2020380366B2 (en) *	2019-11-06	2025-02-13	Kite Pharma, Inc.	Chimeric antigen receptor T cell therapy
BR112022010206A2 (pt) *	2019-11-26	2022-11-29	Novartis Ag	Receptores de antígeno quiméricos e usos dos mesmos
IL292924A (en)	2019-11-26	2022-07-01	Novartis Ag	Cd19 and cd22 chimeric antigen receptors and uses thereof
KR20220131253A (ko) *	2019-12-30	2022-09-27	차이나 이뮤노테크 (베이징) 바이오테크놀로지 컴퍼니 리미티드	향상된 t-세포 수용체 star 및 이의 적용
CN113088540B (zh) *	2020-01-08	2024-12-06	上海交通大学医学院附属瑞金医院	一种gm-csf敲低的t细胞及其用途
EP4093857A4 (en)	2020-01-23	2024-02-21	The Children's Medical Center Corporation	DIFFERENTIATION OF STROMA-FREE T CELLS FROM HUMAN PLURIPOTENT STEM CELLS
CN115175695A (zh)	2020-02-27	2022-10-11	诺华股份有限公司	制备表达嵌合抗原受体的细胞的方法
CA3173737A1 (en)	2020-02-27	2021-09-02	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells
WO2022074464A2 (en)	2020-03-05	2022-04-14	Neotx Therapeutics Ltd.	Methods and compositions for treating cancer with immune cells
CN115335407B (zh) *	2020-03-25	2024-08-27	北京艺妙神州医药科技有限公司	结合cd19的嵌合抗原受体及其用途
WO2021232864A1 (zh) *	2020-05-18	2021-11-25	佧珐药业有限公司	免疫效应细胞治疗肿瘤
EP4162269A1 (en)	2020-06-08	2023-04-12	Janssen Biotech, Inc.	Cell-based assay for determining the in vitro tumor killing activity of chimeric antigen expressing immune cells
BR112022026284A2 (pt)	2020-06-22	2023-03-07	Ngm Biopharmaceuticals Inc	Agentes de ligação, anticorpo, composição farmacêutica, polinucleotídeos, vetores, célula isolada, métodos para interromper, inibir ou bloquear a ligação de lair-1, a atividade de uma célula supressora derivada de mieloide (mdsc), ou a atividade de uma célula t regulatória (treg), método para tratar câncer em um indivíduo, método para inibir o crescimento tumoral, método para aumentar ou intensificar uma resposta imunológica a um tumor ou células tumorais, método para ativar ou intensificar uma resposta imunológica persistente ou a longo prazo a um tumor ou células tumorais, método para inibir a recidiva tumoral ou novo crescimento tumoral, método para induzir uma imunidade persistente ou a longo prazo que inibe recidiva tumoral ou novo crescimento tumoral, método para ativar célula mieloides no microambiente tumoral em um indivíduo com um tumor, método para ativar célula t no microambiente tumoral em um indivíduo com um tumor, método para produzir o agente de ligação
US20230338422A1 (en) *	2020-07-09	2023-10-26	Nanjing Legend Biotech Co., Ltd.	Engineering gamma delta t cells with interleukin-36 for immunotherapy
WO2022031597A1 (en)	2020-08-03	2022-02-10	Kyverna Therapeutics, Inc.	Methods of producing t regulatory cells, methods of transducing t cells, and uses of the same
IL300489A (en)	2020-08-21	2023-04-01	Novartis Ag	Compositions and methods for in vivo production of CAR expressing cells
CN111944850B (zh) *	2020-08-28	2023-03-31	澳门大学	表达抗cd22嵌合抗原受体和pd-l1阻断蛋白的细胞的制备方法、表达载体及应用
CN116529266A (zh)	2020-08-31	2023-08-01	耶鲁大学	用于将核酸递送到细胞的组合物和方法
CN113368262A (zh) *	2020-09-03	2021-09-10	上海易慕峰生物科技有限公司	通过实体肿瘤转移动物模型获取中间结果的方法
WO2022097061A1 (en)	2020-11-06	2022-05-12	Novartis Ag	Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
WO2022133169A1 (en)	2020-12-18	2022-06-23	Century Therapeutics, Inc.	Chimeric antigen receptor systems with adaptable receptor specificity
WO2022165419A1 (en)	2021-02-01	2022-08-04	Kyverna Therapeutics, Inc.	Methods for increasing t-cell function
AR125468A1 (es)	2021-04-27	2023-07-19	Novartis Ag	Sistema de producción de vectores virales
AU2022274608A1 (en) *	2021-05-14	2023-11-09	Kite Pharma, Inc.	Chimeric antigen receptor t cell therapy
EP4349857A4 (en)	2021-05-25	2025-06-11	Vaxcell-Bio	Monobody-based chimeric antigen receptor and immune cell including same
JP2024528077A (ja) *	2021-07-30	2024-07-26	▲い▼尊生物医薬（浙江）有限公司	汎用型ｔ細胞およびその応用
TW202323521A (zh)	2021-08-20	2023-06-16	瑞士商諾華公司	製備表現嵌合抗原受體的細胞之方法
PE20241173A1 (es)	2021-10-14	2024-05-28	Arsenal Biosciences Inc	Celulas inmunitarias que tienen arnhc coexpresados y sistemas de compuerta logica
WO2023081715A1 (en)	2021-11-03	2023-05-11	Viracta Therapeutics, Inc.	Combination of car t-cell therapy with btk inhibitors and methods of use thereof
EP4456927A1 (en)	2021-12-30	2024-11-06	TR1X, Inc.	Cd4t cells expressing il-10 and chimeric antigen receptors and uses thereof
AU2023229697A1 (en)	2022-03-08	2024-09-19	Vaxcell-Bio Co., Ltd.	Pd-l1-specific chimeric antigen receptor and immune cell comprising same
CN119562820A (zh)	2022-05-17	2025-03-04	优莫佳生物制药股份有限公司	制造病毒颗粒
EP4561537A2 (en) *	2022-07-27	2025-06-04	Trustees Of Tufts College	Lipid nanoparticles for immunotherapy
CN115820742A (zh) *	2022-08-10	2023-03-21	国睿(广州)生物科技有限公司	一种提高nk细胞慢病毒转导效率的方法
WO2024081736A2 (en)	2022-10-11	2024-04-18	Yale University	Compositions and methods of using cell-penetrating antibodies
CN120112650A (zh)	2022-10-26	2025-06-06	诺华股份有限公司	慢病毒配制品
TW202434735A (zh)	2022-11-04	2024-09-01	美商烏莫賈生物製藥股份有限公司	展示黏著分子融合的顆粒
AU2023371640A1 (en)	2022-11-04	2025-05-15	Umoja Biopharma, Inc.	Lentiviral particles displaying fusion molecules and uses thereof
IL320934A (en)	2022-12-01	2025-07-01	Univ Yale	A traceless, stimulus-responsive engineered platform for intracellular cargo delivery
CN116410336B (zh) *	2023-06-02	2023-09-22	云南赛元生物技术有限公司	一种嵌合抗原受体的编码核苷酸、car-nk细胞及其构建方法和应用
WO2025079987A2 (ko) *	2023-10-10	2025-04-17	서울대학교산학협력단	키메라 항원 수용체를 발현하는 자연 살해 세포를 이용한 종양 미세환경의 주피세포를 표적하는 항암 세포 치료 기법 및 치료 효능 평가를 위한 종양 미세환경 오가노이드 모델 제작 기술

Family Cites Families (275)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US44768A (en)		1864-10-18		Improvement in coftn-shellers
FR901228A (fr)	1943-01-16	1945-07-20	Deutsche Edelstahlwerke Ag	Système d'aimant à entrefer annulaire
ZA737247B (en)	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
DE3381783D1 (de)	1982-03-03	1990-09-13	Genentech Inc	Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen.
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4882282A (en)	1985-08-16	1989-11-21	Immunex Corporation	DNA sequences encoding bovine interleukin-2
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5906936A (en)	1988-05-04	1999-05-25	Yeda Research And Development Co. Ltd.	Endowing lymphocytes with antibody specificity
US6303121B1 (en)	1992-07-30	2001-10-16	Advanced Research And Technology	Method of using human receptor protein 4-1BB
US6905680B2 (en)	1988-11-23	2005-06-14	Genetics Institute, Inc.	Methods of treating HIV infected subjects
US6352694B1 (en)	1994-06-03	2002-03-05	Genetics Institute, Inc.	Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en)	1988-11-23	2003-03-18	Genetics Institute, Inc.	Methods for selectively stimulating proliferation of T cells
US5858358A (en)	1992-04-07	1999-01-12	The United States Of America As Represented By The Secretary Of The Navy	Methods for selectively stimulating proliferation of T cells
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
US5399346A (en)	1989-06-14	1995-03-21	The United States Of America As Represented By The Department Of Health And Human Services	Gene therapy
US5585362A (en)	1989-08-22	1996-12-17	The Regents Of The University Of Michigan	Adenovirus vectors for gene therapy
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US6319494B1 (en)	1990-12-14	2001-11-20	Cell Genesys, Inc.	Chimeric chains for receptor-associated signal transduction pathways
CA2074825C (en)	1990-12-14	2005-04-12	Daniel J. Capon	Chimeric chains for receptor-associated signal transduction pathways
US7049136B2 (en)	1991-03-07	2006-05-23	The General Hospital Corporation	Redirection of cellular immunity by receptor chimeras
IL101147A (en)	1991-03-07	2004-06-20	Gen Hospital Corp	Redirection of cellular immunity by receptor chimeras
US6004811A (en)	1991-03-07	1999-12-21	The Massachussetts General Hospital	Redirection of cellular immunity by protein tyrosine kinase chimeras
EP0519596B1 (en)	1991-05-17	2005-02-23	Merck & Co. Inc.	A method for reducing the immunogenicity of antibody variable domains
US5199942A (en)	1991-06-07	1993-04-06	Immunex Corporation	Method for improving autologous transplantation
AU675916B2 (en)	1991-06-14	1997-02-27	Genentech Inc.	Method for making humanized antibodies
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
GB9125768D0 (en)	1991-12-04	1992-02-05	Hale Geoffrey	Therapeutic method
ATE249840T1 (de)	1991-12-13	2003-10-15	Xoma Corp	Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
GB9203459D0 (en)	1992-02-19	1992-04-08	Scotgen Ltd	Antibodies with germ-line variable regions
IL104570A0 (en)	1992-03-18	1993-05-13	Yeda Res & Dev	Chimeric genes and cells transformed therewith
US8211422B2 (en)	1992-03-18	2012-07-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Chimeric receptor genes and cells transformed therewith
US5350674A (en)	1992-09-04	1994-09-27	Becton, Dickinson And Company	Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
GB9221220D0 (en)	1992-10-09	1992-11-25	Sandoz Ag	Organic componds
US7211259B1 (en)	1993-05-07	2007-05-01	Immunex Corporation	4-1BB polypeptides and DNA encoding 4-1BB polypeptides
NZ273838A (en)	1993-09-16	1997-09-22	Indiana University Foundation	Human receptor protein h4-1bb
CA2175215C (en)	1993-11-19	2008-06-03	Yat Sun Or	Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
BR9408323A (pt)	1993-12-17	1997-08-19	Sandoz Ag	Derivados de rapamicina
US5362718A (en)	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
AU694222B2 (en)	1994-05-02	1998-07-16	Bernd Groner	Bifunctional protein, preparation and use
US7175843B2 (en)	1994-06-03	2007-02-13	Genetics Institute, Llc	Methods for selectively stimulating proliferation of T cells
US5786464C1 (en)	1994-09-19	2012-04-24	Gen Hospital Corp	Overexpression of mammalian and viral proteins
US5712149A (en)	1995-02-03	1998-01-27	Cell Genesys, Inc.	Chimeric receptor molecules for delivery of co-stimulatory signals
US6103521A (en)	1995-02-06	2000-08-15	Cell Genesys, Inc.	Multispecific chimeric receptors
HU225688B1 (en)	1995-02-24	2007-06-28	Gen Hospital Corp	Redirection of cellular immunity by receptor chimeras
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US6692964B1 (en)	1995-05-04	2004-02-17	The United States Of America As Represented By The Secretary Of The Navy	Methods for transfecting T cells
US7067318B2 (en)	1995-06-07	2006-06-27	The Regents Of The University Of Michigan	Methods for transfecting T cells
US5985890A (en)	1995-06-09	1999-11-16	Novartis Ag	Rapamycin derivatives
BE1009856A5 (fr)	1995-07-14	1997-10-07	Sandoz Sa	Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
GB9526131D0 (en)	1995-12-21	1996-02-21	Celltech Therapeutics Ltd	Recombinant chimeric receptors
WO1997031898A1 (en)	1996-02-28	1997-09-04	Ariad Gene Therapeutics, Inc.	Synthetic derivatives of rapamycin as multimerizing agents for chimeric proteins with immunophilin-derived domains
US5874240A (en)	1996-03-15	1999-02-23	Human Genome Sciences, Inc.	Human 4-1BB receptor splicing variant
EP0937082A2 (en)	1996-07-12	1999-08-25	Ariad Pharmaceuticals, Inc.	Materials and method for treating or preventing pathogenic fungal infection
ES2308787T3 (es)	1996-08-16	2008-12-01	Schering Corporation	Antigenos de superficie de celular de mamiferos; reactivos relacionados.
US6111090A (en)	1996-08-16	2000-08-29	Schering Corporation	Mammalian cell surface antigens; related reagents
US6114148C1 (en)	1996-09-20	2012-05-01	Gen Hospital Corp	High level expression of proteins
JP2002512502A (ja)	1996-10-25	2002-04-23	セル・ジェネシス・インコーポレイテッド	癌細胞の標的細胞溶解
US6673901B2 (en)	1997-06-12	2004-01-06	Research Corporation Technologies, Inc.	Artificial antibody polypeptides
US20030060444A1 (en)	1997-06-25	2003-03-27	Celltech Therapeutics, Ltd.	Cell activation process and reagents therefor
GB9713473D0 (en)	1997-06-25	1997-09-03	Celltech Therapeutics Ltd	Biological products
WO1999015555A1 (en) *	1997-09-19	1999-04-01	The General Hospital Corporation	Car receptors and related molecules and methods
US6015815A (en)	1997-09-26	2000-01-18	Abbott Laboratories	Tetrazole-containing rapamycin analogs with shortened half-lives
TW557297B (en)	1997-09-26	2003-10-11	Abbott Lab	Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
JP2001520039A (ja)	1997-10-21	2001-10-30	ヒューマンジノームサイエンシーズ，インコーポレイテッド	ヒト腫瘍壊死因子レセプター様タンパク質、ｔｒ１１，ｔｒ１１ｓｖ１およびｔｒ１１ｓｖ２
AU748143B2 (en)	1997-10-28	2002-05-30	University Of British Columbia, The	Immunological compositions and methods of use to transiently alter mammalian central nervous system myelin to promote neuronal regeneration
WO1999040196A1 (en)	1998-02-09	1999-08-12	Genentech, Inc.	Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
US20040040047A1 (en)	1998-03-30	2004-02-26	Spencer David M.	Regulated apoptosis using chemically induced dimerization of apoptosis factors
DE69925909T2 (de)	1998-04-15	2006-05-11	Brigham & Women's Hospital, Inc., Boston	T-zell inhibierende rezeptorzusammensetzungen sowie deren verwendung
GB9809658D0 (en)	1998-05-06	1998-07-01	Celltech Therapeutics Ltd	Biological products
WO2000014257A1 (en)	1998-09-04	2000-03-16	Sloan-Kettering Institute For Cancer Research	Fusion receptors specific for prostate-specific membrane antigen and uses thereof
US6410319B1 (en)	1998-10-20	2002-06-25	City Of Hope	CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
JP2002541845A (ja)	1999-04-16	2002-12-10	セルテックセラピューティックスリミテッド	合成膜貫通成分
JP2003504343A (ja)	1999-07-12	2003-02-04	ジェネンテック・インコーポレーテッド	腫瘍壊死因子リガンド／レセプター相同体による血管形成及び心血管形成の促進と抑制
DE60010098T2 (de)	1999-08-24	2005-03-31	Ariad Gene Therapeutics, Inc., Cambridge	28-epirapaloge
WO2001029058A1 (en)	1999-10-15	2001-04-26	University Of Massachusetts	Rna interference pathway genes as tools for targeted genetic interference
GB9925848D0 (en)	1999-11-01	1999-12-29	Celltech Therapeutics Ltd	Biological products
US6326193B1 (en)	1999-11-05	2001-12-04	Cambria Biosciences, Llc	Insect control agent
WO2001034843A1 (en)	1999-11-10	2001-05-17	The Uab Research Foundation	Lentiviral vector transduction of hematopoietic stem cells
US6797514B2 (en)	2000-02-24	2004-09-28	Xcyte Therapies, Inc.	Simultaneous stimulation and concentration of cells
US6867041B2 (en)	2000-02-24	2005-03-15	Xcyte Therapies, Inc.	Simultaneous stimulation and concentration of cells
US7572631B2 (en)	2000-02-24	2009-08-11	Invitrogen Corporation	Activation and expansion of T cells
KR20030032922A (ko)	2000-02-24	2003-04-26	싸이트 테라피스 인코포레이티드	세포의 동시 자극 및 농축
IL136511A0 (en)	2000-06-01	2001-06-14	Gavish Galilee Bio Appl Ltd	Genetically engineered mhc molecules
WO2001096584A2 (en)	2000-06-12	2001-12-20	Akkadix Corporation	Materials and methods for the control of nematodes
GB0025307D0 (en)	2000-10-16	2000-11-29	Celltech Chiroscience Ltd	Biological products
AU2001297703B2 (en)	2000-11-07	2006-10-19	City Of Hope	CD19-specific redirected immune cells
CN1294148C (zh)	2001-04-11	2007-01-10	中国科学院遗传与发育生物学研究所	环状单链三特异抗体
US7070995B2 (en)	2001-04-11	2006-07-04	City Of Hope	CE7-specific redirected immune cells
AU2002256390B2 (en)	2001-04-30	2007-08-30	City Of Hope	Chimeric immunoreceptor useful in treating human cancers
US7514537B2 (en)	2001-04-30	2009-04-07	City Of Hope	Chimeric immunoreceptor useful in treating human gliomas
US20090257994A1 (en)	2001-04-30	2009-10-15	City Of Hope	Chimeric immunoreceptor useful in treating human cancers
US20030148982A1 (en)	2001-11-13	2003-08-07	Brenner Malcolm K.	Bi-spcific chimeric T cells
WO2003057171A2 (en)	2002-01-03	2003-07-17	The Trustees Of The University Of Pennsylvania	Activation and expansion of t-cells using an engineered multivalent signaling platform
US7638326B2 (en)	2002-01-03	2009-12-29	The Trustees Of The University Of Pennsylvania	Activation and expansion of T-cells using an engineered multivalent signaling platform
US7745140B2 (en)	2002-01-03	2010-06-29	The Trustees Of The University Of Pennsylvania	Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
JP4547911B2 (ja)	2002-02-01	2010-09-22	アリアド・ファーマシューティカルズ・インコーポレイテッド	リン含有化合物およびその用途
GB0208104D0 (en)	2002-04-09	2002-05-22	Univ Dundee	Method
US7446190B2 (en)	2002-05-28	2008-11-04	Sloan-Kettering Institute For Cancer Research	Nucleic acids encoding chimeric T cell receptors
ES2263984T3 (es)	2002-06-28	2006-12-16	Domantis Limited	Ligandos doble-especificos con una vida media serica aumentada.
US20040047858A1 (en)	2002-09-11	2004-03-11	Blumberg Richard S.	Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
AU2003288675B2 (en)	2002-12-23	2010-07-22	Medimmune Limited	Antibodies against PD-1 and uses therefor
US20050129671A1 (en)	2003-03-11	2005-06-16	City Of Hope	Mammalian antigen-presenting T cells and bi-specific T cells
US7402431B2 (en)	2004-03-01	2008-07-22	Immunovative Therapies, Ltd.	T-cell therapy formulation
NZ543654A (en)	2003-05-23	2009-05-31	Wyeth Corp	GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
KR20060041205A (ko)	2003-07-01	2006-05-11	이뮤노메딕스, 인코오포레이티드	양특이성 항체들의 다가 담체들
EP1660126A1 (en)	2003-07-11	2006-05-31	Schering Corporation	Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
US20050048617A1 (en)	2003-08-18	2005-03-03	Medimmune, Inc.	Humanization of antibodies
US8198020B2 (en)	2003-08-22	2012-06-12	Potentia Pharmaceuticals, Inc.	Compositions and methods for enhancing phagocytosis or phagocyte activity
US20050042664A1 (en)	2003-08-22	2005-02-24	Medimmune, Inc.	Humanization of antibodies
US20050113564A1 (en)	2003-11-05	2005-05-26	St. Jude Children's Research Hospital	Chimeric receptors with 4-1BB stimulatory signaling domain
US7435596B2 (en)	2004-11-04	2008-10-14	St. Jude Children's Research Hospital, Inc.	Modified cell line and method for expansion of NK cell
US7220755B2 (en)	2003-11-12	2007-05-22	Biosensors International Group, Ltd.	42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
JP2007518399A (ja)	2003-12-02	2007-07-12	ジェンザイムコーポレイション	肺癌を診断および治療する組成物並びに方法
GB0409799D0 (en)	2004-04-30	2004-06-09	Isis Innovation	Method of generating improved immune response
WO2005118788A2 (en)	2004-05-27	2005-12-15	The Trustees Of The University Of Pennsylvania	Novel artificial antigen presenting cells and uses therefor
WO2006083289A2 (en)	2004-06-04	2006-08-10	Duke University	Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
EP1786918A4 (en)	2004-07-17	2009-02-11	Imclone Systems Inc	NEW BISPECIFIC ANTIBODY TETRAVALENT
WO2006036445A2 (en)	2004-09-24	2006-04-06	Trustees Of Dartmouth College	Chimeric nk receptor and methods for treating cancer
WO2006060878A1 (en)	2004-12-10	2006-06-15	Peter Maccallum Cancer Institute	Methods and compositions for adoptive immunotherapy
EP2343320B1 (en)	2005-03-25	2017-10-25	GITR, Inc.	Anti-gitr antibodies and uses thereof
EP3530736A3 (en)	2005-05-09	2019-11-06	ONO Pharmaceutical Co., Ltd.	Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
MX2007014474A (es)	2005-05-17	2008-02-07	Univ Connecticut	Composiciones y metodos para inmunomodulacion en un organismo.
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
EP2982379A1 (en)	2005-07-01	2016-02-10	E. R. Squibb & Sons, L.L.C.	Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
US20070036773A1 (en)	2005-08-09	2007-02-15	City Of Hope	Generation and application of universal T cells for B-ALL
CA2618482C (en)	2005-08-19	2014-10-07	Abbott Laboratories	Dual variable domain immunoglobin and uses thereof
CN103819416A (zh)	2005-10-07	2014-05-28	埃克塞里艾克西斯公司	N-(3-氨基-喹喔啉-2-基)-磺酰胺衍生物及其作为磷脂酰肌醇3-激酶抑制剂的用途
MX357691B (es)	2006-01-13	2018-07-19	The Government Of The United States As Represented By The Secretary Of The Department Of Health And	Il-15 y il-15r-alfa mejoradas para expresion en celulas mamiferas.
WO2007133822A1 (en)	2006-01-19	2007-11-22	Genzyme Corporation	Gitr antibodies for the treatment of cancer
US20100105136A1 (en)	2006-10-09	2010-04-29	The General Hospital Corporation	Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
EP1916259A1 (en)	2006-10-26	2008-04-30	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Anti-glycoprotein VI SCFV fragment for treatment of thrombosis
US20080131415A1 (en)	2006-11-30	2008-06-05	Riddell Stanley R	Adoptive transfer of cd8 + t cell clones derived from central memory cells
CA2584494A1 (en)	2007-03-27	2008-09-27	Jeffrey A. Medin	Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
DK2141997T3 (da)	2007-03-30	2013-02-11	Sloan Kettering Inst Cancer	Konstitutiv ekspression af co-stimulatoriske ligander på adoptivt overførte t-lymfocytter
BRPI0812913B8 (pt)	2007-06-18	2021-05-25	Merck Sharp & Dohme	anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos
EP2173378B1 (en)	2007-06-27	2014-03-19	Admune Therapeutics LLC	Complexes of il-15 and il-15ralpha and uses thereof
US8591886B2 (en)	2007-07-12	2013-11-26	Gitr, Inc.	Combination therapies employing GITR binding molecules
CA2703947C (en)	2007-10-26	2018-12-04	Governing Council Of The University Of Toronto	Therapeutic and diagnostic methods using tim-3
WO2009091826A2 (en)	2008-01-14	2009-07-23	The Board Of Regents Of The University Of Texas System	Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
US10059923B2 (en)	2008-01-30	2018-08-28	Memorial Sloan Kettering Cancer Center	Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors
PT2242773T (pt)	2008-02-11	2017-09-15	Cure Tech Ltd	Anticorpos monoclonais para o tratamento de tumores
CN102014912A (zh)	2008-02-21	2011-04-13	阿斯利康(瑞典)有限公司	联合疗法238
US8379824B2 (en)	2008-03-06	2013-02-19	At&T Intellectual Property I, Lp	Methods and apparatus to provide a network-based caller identification service in a voice over internet protocol network
WO2009114335A2 (en)	2008-03-12	2009-09-17	Merck & Co., Inc.	Pd-1 binding proteins
CA2729810A1 (en)	2008-07-02	2010-01-07	Emergent Product Development Seattle, Llc	Tgf-.beta. antagonist multi-target binding proteins
AR072999A1 (es)	2008-08-11	2010-10-06	Medarex Inc	Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
CA2735006A1 (en)	2008-08-25	2010-03-11	Amplimmune, Inc.	Pd-1 antagonists and methods of use thereof
EA023148B1 (ru)	2008-08-25	2016-04-29	Эмплиммьюн, Инк.	Композиции на основе антагонистов pd-1 и их применение
EP3006459B1 (en)	2008-08-26	2021-10-06	City of Hope	Method and compositions for enhanced anti-tumor effector functioning of t cells
JPWO2010030002A1 (ja)	2008-09-12	2012-02-02	国立大学法人三重大学	外来性ｇｉｔｒリガンド発現細胞
US8476282B2 (en)	2008-11-03	2013-07-02	Intellikine Llc	Benzoxazole kinase inhibitors and methods of use
FI4209510T3 (fi)	2008-12-09	2024-03-22	Hoffmann La Roche	Anti-PD-L1-vasta-aineita ja niiden käyttö T-solutoiminnan tehostamiseksi
EP2389443B1 (en)	2009-01-23	2018-11-14	Roger Williams Hospital	Retroviral vectors encoding multiple highly homologous non-viral polypeptides and the use of same
RU2011135768A (ru)	2009-01-29	2013-03-10	Эбботт Лэборетриз	Белки, связывающие il-1
EP2393835B1 (en)	2009-02-09	2017-04-05	Université d'Aix-Marseille	Pd-1 antibodies and pd-l1 antibodies and uses thereof
WO2010095031A2 (en)	2009-02-23	2010-08-26	Glenmark Pharmaceuticals S.A.	Humanized antibodies that bind to cd19 and their uses
MX2011010332A (es)	2009-04-03	2011-11-29	S Bio Pte Ltd	Compuestos de purina sustituidos con pirimidina como inhibidores de cinasa(s).
BRPI1015350B1 (pt)	2009-04-30	2021-08-24	Tel Hashomer Medical Research Infrastructure And Services Ltd	Célula do hibridoma, anticorpo isolado ceacam1 ou fragmento de anticorpo, método para diagnosticar um câncer em um sujeito em necessidade do mesmo e composição farmacêutica
CA2768965C (en)	2009-08-14	2019-06-04	George N. Pavlakis	Use of il-15 to increase thymic output and to treat lymphopenia
CA3067609A1 (en)	2009-09-03	2011-03-10	Merck Sharp & Dohme Corp.	Anti-gitr antibodies
WO2011041093A1 (en)	2009-10-01	2011-04-07	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
US9181527B2 (en)	2009-10-29	2015-11-10	The Trustees Of Dartmouth College	T cell receptor-deficient T cell compositions
GB0919054D0 (en)	2009-10-30	2009-12-16	Isis Innovation	Treatment of obesity
EP4049674A1 (en) *	2009-11-03	2022-08-31	City of Hope	Truncated epidermal growth factor receptor (egfrt) for transduced t cell selection
US8956828B2 (en)	2009-11-10	2015-02-17	Sangamo Biosciences, Inc.	Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
WO2011066342A2 (en)	2009-11-24	2011-06-03	Amplimmune, Inc.	Simultaneous inhibition of pd-l1/pd-l2
AU2010343057B2 (en)	2009-12-29	2017-02-23	Aptevo Research And Development Llc	Heterodimer binding proteins and uses thereof
EP2531216B1 (en)	2010-02-04	2019-03-27	The Trustees Of The University Of Pennsylvania	Icos critically regulates the expansion and function of inflammatory human th17 cells
US9089520B2 (en)	2010-05-21	2015-07-28	Baylor College Of Medicine	Methods for inducing selective apoptosis
CA2802344C (en)	2010-06-18	2023-06-13	The Brigham And Women's Hospital, Inc.	Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
DK3323830T3 (da) *	2010-06-19	2023-09-25	Memorial Sloan Kettering Cancer Center	Anti-gd2 antibodies
KR20130098301A (ko)	2010-07-09	2013-09-04	엑셀리시스, 인코포레이티드	암 치료를 위한 키나제 억제제들의 병용물
WO2012007926A1 (en)	2010-07-16	2012-01-19	Piramal Life Sciences Limited	Substituted imidazoquinoline derivatives as kinase inhibitors
CA2805442C (en)	2010-07-21	2020-05-12	Sangamo Biosciences, Inc.	Methods and compositions for modification of an hla locus
WO2012050374A2 (en) *	2010-10-13	2012-04-19	Innocell, Inc.	Immunotherapy for solid tumors
NZ609967A (en)	2010-10-27	2015-04-24	Baylor College Medicine	Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
PH12013501201A1 (en)	2010-12-09	2013-07-29	Univ Pennsylvania	Use of chimeric antigen receptor-modified t cells to treat cancer
EP2651442B1 (en)	2010-12-14	2020-04-22	University of Maryland, Baltimore	Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
JP2014509841A (ja)	2011-01-18	2014-04-24	ザトラスティーズオブザユニバーシティオブペンシルバニア	癌を治療するための組成物および方法
KR101440529B1 (ko) *	2011-03-18	2014-09-17	주식회사 엘지화학	디니트릴 화합물의 제조방법
WO2012127464A2 (en)	2011-03-23	2012-09-27	Gavish-Galilee Bio Applications Ltd	Constitutively activated t cells for use in adoptive cell therapy
RU2688185C2 (ru)	2011-03-23	2019-05-21	Фред Хатчинсон Кэнсер Рисерч Сентер	Способ и композиции для клеточной иммунотерапии
MY160662A (en)	2011-04-01	2017-03-15	Memorial Sloan Kettering Cancer Center	T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
EP2694549B1 (en)	2011-04-08	2018-08-15	The United States of America, as represented by The Secretary, Department of Health and Human Services	Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
NZ723731A (en)	2011-04-08	2020-05-29	Baylor College Medicine	Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
US20130071414A1 (en)	2011-04-27	2013-03-21	Gianpietro Dotti	Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
WO2013006490A2 (en)	2011-07-01	2013-01-10	Cellerant Therapeutics, Inc.	Antibodies that specifically bind to tim3
WO2013016352A1 (en)	2011-07-25	2013-01-31	Nationwide Children's Hospital, Inc.	Recombinant virus products and methods for inhibition of expression of dux4
EP3549611B1 (en)	2011-07-29	2021-06-30	The Trustees of the University of Pennsylvania	Switch costimulatory receptors
HK1199203A1 (en)	2011-08-11	2015-06-26	Intellikine, Llc	Kinase inhibitor polymorphs
US9833476B2 (en)	2011-08-31	2017-12-05	The Trustees Of Dartmouth College	NKP30 receptor targeted therapeutics
WO2013039954A1 (en)	2011-09-14	2013-03-21	Sanofi	Anti-gitr antibodies
DK2755487T3 (en)	2011-09-16	2019-04-08	Baylor College Medicine	TARGETATION OF THE TUMORMICROMY ENVIRONMENT USING MANIPULATED NKT CELLS
EP2756521A4 (en)	2011-09-16	2015-04-22	Univ Pennsylvania	RNA-MANIPULATED T-CELLS FOR THE TREATMENT OF CANCER
WO2013054320A1 (en)	2011-10-11	2013-04-18	Tel Hashomer Medical Research Infrastructure And Services Ltd.	Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
CN104039325A (zh) *	2011-10-19	2014-09-10	药品循环公司	布鲁顿酪氨酸激酶(btk)抑制剂的用途
IN2014CN02906A (ko)	2011-10-20	2015-07-03	Us Health
US20130131139A1 (en) *	2011-11-17	2013-05-23	Oregon Health & Science University	Ror1 as a gene target in acute lymphoblastic leukemia
JP6385277B2 (ja)	2011-12-01	2018-09-05	ザブリガムアンドウィメンズホスピタルインコーポレイテッドＴｈｅＢｒｉｇｈａｍａｎｄＷｏｍｅｎ’ｓＨｏｓｐｉｔａｌ，Ｉｎｃ．	癌治療のための抗ｃｅａｃａｍ１組換え型抗体
US9783591B2 (en)	2012-02-22	2017-10-10	The Trustees Of The University Of Pennsylvania	Use of the CD2 signaling domain in second-generation chimeric antigen receptors
MX2014010183A (es)	2012-02-22	2015-03-20	Univ Pennsylvania	Composiciones y metodos para generar una poblacion persistente de celulas t utiles para el tratamiento de cancer.
IN2014DN07414A (ko)	2012-02-22	2015-04-24	Univ Pennsylvania
LT4289948T (lt)	2012-05-25	2025-05-12	The Regents Of The University Of California	Į rnr nukreipto tikslinio dnr modifikavimo ir į rnr nukreipto transkripcijos moduliavimo metodai ir kompozicijos
EP3721901A1 (en) *	2012-07-13	2020-10-14	The Trustees of the University of Pennsylvania	Toxicity management for anti-tumor activity of cars
CA2878862C (en)	2012-07-13	2023-01-10	The Trustees Of The University Of Pennsylvania	Methods of assessing the suitability of transduced t cells for administration
EP2872617A4 (en)	2012-07-13	2015-12-09	Univ Pennsylvania	EPITOP SPREADING IN CONNECTION WITH CAR T CELLS
EA201590207A1 (ru)	2012-07-13	2015-05-29	Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания	Композиции и способы регуляции car-т-клеток
IN2015DN00139A (ko)	2012-07-13	2015-06-12	Univ Pennsylvania
US9765156B2 (en)	2012-07-13	2017-09-19	The Trustees Of The University Of Pennsylvania	Enhancing activity of CAR T cells by co-introducing a bispecific antibody
EP2879709B1 (en)	2012-07-31	2020-01-08	The Brigham and Women's Hospital, Inc.	Modulation of the immune response
MX380109B (es)	2012-08-20	2025-03-12	Fred Hutchinson Cancer Center Star	Metodo y composiciones para inmunoterapia celular.
WO2014039513A2 (en)	2012-09-04	2014-03-13	The Trustees Of The University Of Pennsylvania	Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
US9365641B2 (en)	2012-10-01	2016-06-14	The Trustees Of The University Of Pennsylvania	Compositions and methods for targeting stromal cells for the treatment of cancer
WO2014055657A1 (en)	2012-10-05	2014-04-10	The Trustees Of The University Of Pennsylvania	Use of a trans-signaling approach in chimeric antigen receptors
KR102229873B1 (ko)	2012-10-12	2021-03-19	더 브리검 앤드 우먼즈 하스피털, 인크.	면역 반응의 향상
SG10201912327SA (en)	2012-12-12	2020-02-27	Broad Inst Inc	Engineering and Optimization of Improved Systems, Methods and Enzyme Compositions for Sequence Manipulation
CA2894668A1 (en)	2012-12-12	2014-06-19	The Broad Institute, Inc.	Crispr-cas systems and methods for altering expression of gene products in eukaryotic cells
US8697359B1 (en)	2012-12-12	2014-04-15	The Broad Institute, Inc.	CRISPR-Cas systems and methods for altering expression of gene products
WO2014110591A1 (en)	2013-01-14	2014-07-17	Fred Hutchinson Cancer Research Center	Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse
EP3881868B1 (en)	2013-02-15	2023-09-27	The Regents Of The University Of California	Chimeric antigen receptor and methods of use thereof
KR102509562B1 (ko)	2013-02-20	2023-03-14	노파르티스 아게	인간화 항-EGFRvIII 키메라 항원 수용체를 사용한 암의 치료
ES2814962T3 (es)	2013-02-20	2021-03-29	Novartis Ag	Fijación eficaz como objetivo de la leucemia humana primaria utilizando células T modificadas con receptor de antígeno quimérico anti-CD123
US9434935B2 (en)	2013-03-10	2016-09-06	Bellicum Pharmaceuticals, Inc.	Modified caspase polypeptides and uses thereof
KR20150131218A (ko)	2013-03-14	2015-11-24	벨리쿰 파마슈티컬스, 인크.	T 세포 증식의 제어 방법
US9745368B2 (en)	2013-03-15	2017-08-29	The Trustees Of The University Of Pennsylvania	Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
US9657105B2 (en) *	2013-03-15	2017-05-23	City Of Hope	CD123-specific chimeric antigen receptor redirected T cells and methods of their use
TWI654206B (zh) *	2013-03-16	2019-03-21	諾華公司	使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
EP3004329B1 (en)	2013-06-05	2020-03-04	Bellicum Pharmaceuticals, Inc.	Methods for inducing partial apoptosis using caspase polypeptides
JP6637415B2 (ja) *	2013-10-15	2020-01-29	ザスクリプスリサーチインスティテュート	キメラ抗原受容体ｔ細胞スイッチおよびその使用
US9512084B2 (en)	2013-11-29	2016-12-06	Novartis Ag	Amino pyrimidine derivatives
IL263466B2 (en) *	2013-12-17	2023-10-01	Genentech Inc	Anti-cd3 antibodies and methods of use
CA3225453A1 (en)	2013-12-19	2015-06-25	Novartis Ag	Human mesothelin chimeric antigen receptors and uses thereof
US10287354B2 (en)	2013-12-20	2019-05-14	Novartis Ag	Regulatable chimeric antigen receptor
ES2963718T3 (es)	2014-01-21	2024-04-01	Novartis Ag	Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras
US20170081411A1 (en)	2014-03-15	2017-03-23	Novartis Ag	Regulatable chimeric antigen receptor
EP3119423B1 (en)	2014-03-15	2022-12-14	Novartis AG	Treatment of cancer using chimeric antigen receptor
NZ724368A (en) *	2014-03-19	2023-07-28	Infinity Pharmaceuticals Inc	Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
RU2718542C2 (ru)	2014-04-07	2020-04-08	Новартис Аг	Лечение злокачественной опухоли с использованием химерного рецептора антигена против cd19
WO2016014553A1 (en)	2014-07-21	2016-01-28	Novartis Ag	Sortase synthesized chimeric antigen receptors
EP3194585A1 (en)	2014-07-21	2017-07-26	Novartis AG	Sortase molecules and uses thereof
TWI750110B (zh)	2014-07-21	2021-12-21	瑞士商諾華公司	使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
US20170274014A1 (en)	2014-07-21	2017-09-28	Jennifer Brogdon	Combinations of low, immune enhancing, doses of mtor inhibitors and cars
TWI719942B (zh)	2014-07-21	2021-03-01	瑞士商諾華公司	使用ｃｄ３３嵌合抗原受體治療癌症
JP2017528433A (ja)	2014-07-21	2017-09-28	ノバルティスアーゲー	低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
CA2955465A1 (en)	2014-07-21	2016-01-28	Novartis Ag	Treatment of cancer using a cll-1 chimeric antigen receptor
EP3174546B1 (en)	2014-07-31	2019-10-30	Novartis AG	Subset-optimized chimeric antigen receptor-containing t-cells
US10851149B2 (en)	2014-08-14	2020-12-01	The Trustees Of The University Of Pennsylvania	Treatment of cancer using GFR α-4 chimeric antigen receptor
PL3183268T3 (pl)	2014-08-19	2020-09-07	Novartis Ag	Chimeryczny receptor antygenowy (CAR) anty-CD123 do zastosowania w leczeniu nowotworu złośliwego
PL3194443T3 (pl)	2014-09-17	2022-01-31	Novartis Ag	Nakierowywanie komórek cytotoksycznych za pośrednictwem receptorów chimerycznych do immunoterapii adoptywnej
CN106973568B (zh)	2014-10-08	2021-07-23	诺华股份有限公司	预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
WO2016061368A1 (en)	2014-10-15	2016-04-21	The Children's Hospital Of Philadelphia	Compositions and methods for treating b-lymphoid malignancies
IL253149B2 (en)	2014-12-29	2023-11-01	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells
WO2016115482A1 (en)	2015-01-16	2016-07-21	Novartis Pharma Ag	Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
WO2016126608A1 (en)	2015-02-02	2016-08-11	Novartis Ag	Car-expressing cells against multiple tumor antigens and uses thereof
US20180140602A1 (en)	2015-04-07	2018-05-24	Novartis Ag	Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
ES2923894T3 (es) *	2015-04-08	2022-10-03	Novartis Ag	Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
AU2016249005B2 (en)	2015-04-17	2022-06-16	Novartis Ag	Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
WO2016172583A1 (en)	2015-04-23	2016-10-27	Novartis Ag	Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
AU2016297014B2 (en)	2015-07-21	2021-06-17	Novartis Ag	Methods for improving the efficacy and expansion of immune cells
US11667691B2 (en)	2015-08-07	2023-06-06	Novartis Ag	Treatment of cancer using chimeric CD3 receptor proteins
US11747346B2 (en)	2015-09-03	2023-09-05	Novartis Ag	Biomarkers predictive of cytokine release syndrome
KR20180051625A (ko)	2015-09-17	2018-05-16	노파르티스 아게	증진된 효능을 갖는 car t 세포 요법
CN108603200B (zh) *	2015-11-23	2022-08-19	诺华股份有限公司	优化的慢病毒转移载体及其用途
KR20240153612A (ko) *	2016-10-07	2024-10-23	노파르티스 아게	암의 치료를 위한 키메라 항원 수용체
WO2019213282A1 (en) *	2018-05-01	2019-11-07	Novartis Ag	Biomarkers for evaluating car-t cells to predict clinical outcome
US20210213063A1 (en) *	2018-05-25	2021-07-15	Novartis Ag	Combination therapy with chimeric antigen receptor (car) therapies
IL278951B (en) *	2018-07-10	2022-08-01	Novartis Ag	3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
AR116109A1 (es) *	2018-07-10	2021-03-31	Novartis Ag	Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
BR112022010206A2 (pt) *	2019-11-26	2022-11-29	Novartis Ag	Receptores de antígeno quiméricos e usos dos mesmos
IL292924A (en) *	2019-11-26	2022-07-01	Novartis Ag	Cd19 and cd22 chimeric antigen receptors and uses thereof
US20240033358A1 (en) *	2020-11-13	2024-02-01	Novartis Ag	Combination therapies with chimeric antigen receptor (car)-expressing cells

2015
- 2015-04-07 RU RU2016142896A patent/RU2718542C2/ru active
- 2015-04-07 KR KR1020247009639A patent/KR20240042250A/ko not_active Ceased
- 2015-04-07 CN CN201580018102.9A patent/CN107075482B/zh active Active
- 2015-04-07 EP EP21160203.2A patent/EP3888674B1/en active Active
- 2015-04-07 PL PL15719043T patent/PL3129470T3/pl unknown
- 2015-04-07 DK DK15719043.0T patent/DK3129470T3/da active
- 2015-04-07 PL PL21160203.2T patent/PL3888674T3/pl unknown
- 2015-04-07 PT PT157190430T patent/PT3129470T/pt unknown
- 2015-04-07 TW TW104111176A patent/TWI753848B/zh active
- 2015-04-07 IL IL293603A patent/IL293603B2/en unknown
- 2015-04-07 IL IL280215A patent/IL280215B/en unknown
- 2015-04-07 ES ES15719043T patent/ES2876263T3/es active Active
- 2015-04-07 IL IL307423A patent/IL307423A/en unknown
- 2015-04-07 KR KR1020167027427A patent/KR102487608B1/ko active Active
- 2015-04-07 SI SI201531647T patent/SI3129470T1/sl unknown
- 2015-04-07 KR KR1020237000827A patent/KR102651707B1/ko active Active
- 2015-04-07 EP EP15719043.0A patent/EP3129470B1/en active Active
- 2015-04-07 FI FIEP21160203.2T patent/FI3888674T3/fi active
- 2015-04-07 CA CA2940671A patent/CA2940671A1/en active Pending
- 2015-04-07 US US14/680,860 patent/US10357514B2/en active Active
- 2015-04-07 MY MYPI2016702996A patent/MY191608A/en unknown
- 2015-04-07 HR HRP20211055TT patent/HRP20211055T1/hr unknown
- 2015-04-07 HU HUE21160203A patent/HUE066973T2/hu unknown
- 2015-04-07 HU HUE15719043A patent/HUE054588T2/hu unknown
- 2015-04-07 PT PT211602032T patent/PT3888674T/pt unknown
- 2015-04-07 JP JP2016561313A patent/JP6765966B2/ja active Active
- 2015-04-07 DK DK21160203.2T patent/DK3888674T3/da active
- 2015-04-07 EP EP24166976.1A patent/EP4406610A3/en active Pending
- 2015-04-07 LT LTEP21160203.2T patent/LT3888674T/lt unknown
- 2015-04-07 SI SI201532018T patent/SI3888674T1/sl unknown
- 2015-04-07 ES ES21160203T patent/ES2988631T3/es active Active
- 2015-04-07 SG SG11201606909RA patent/SG11201606909RA/en unknown
- 2015-04-07 LT LTEP15719043.0T patent/LT3129470T/lt unknown
- 2015-04-07 WO PCT/US2015/024671 patent/WO2015157252A1/en active Application Filing
- 2015-04-07 HR HRP20240874TT patent/HRP20240874T1/hr unknown
- 2015-04-07 AU AU2015244039A patent/AU2015244039B2/en active Active
- 2015-04-07 SG SG10202109752X patent/SG10202109752XA/en unknown
- 2015-04-07 CN CN202010128384.0A patent/CN111514283A/zh active Pending
- 2015-04-07 MX MX2016013239A patent/MX395149B/es unknown
2016
- 2016-08-10 IL IL247204A patent/IL247204B/en active IP Right Grant
- 2016-08-16 ZA ZA2016/05657A patent/ZA201605657B/en unknown
- 2016-10-07 MX MX2022010623A patent/MX2022010623A/es unknown
2019
- 2019-06-07 US US16/435,257 patent/US20190388471A1/en active Pending
2020
- 2020-03-11 JP JP2020041499A patent/JP7258802B2/ja active Active
2022
- 2022-01-18 AU AU2022200288A patent/AU2022200288B2/en active Active
2023
- 2023-04-05 JP JP2023061386A patent/JP2023085460A/ja active Pending
2025
- 2025-02-07 AU AU2025200842A patent/AU2025200842A1/en active Pending

Also Published As

Publication number	Publication date
KR102487608B1 (ko)	2023-01-12
LT3129470T (lt)	2021-07-12
AU2022200288B2 (en)	2024-11-07
JP2023085460A (ja)	2023-06-20
HUE066973T2 (hu)	2024-09-28
ES2876263T3 (es)	2021-11-12
IL307423A (en)	2023-12-01
JP2017517488A (ja)	2017-06-29
PL3129470T3 (pl)	2021-11-29
US20150283178A1 (en)	2015-10-08
DK3888674T3 (da)	2024-07-08
SI3888674T1 (sl)	2024-08-30
AU2025200842A1 (en)	2025-02-27
CN107075482A (zh)	2017-08-18
JP7258802B2 (ja)	2023-04-17
CN111514283A (zh)	2020-08-11
EP3129470B1 (en)	2021-04-07
AU2015244039B2 (en)	2021-10-21
TW201600092A (zh)	2016-01-01
WO2015157252A8 (en)	2016-08-04
JP2020121975A (ja)	2020-08-13
IL293603B1 (en)	2023-11-01
KR20160135233A (ko)	2016-11-25
IL280215A (en)	2021-03-01
CN107075482B (zh)	2021-03-16
SG11201606909RA (en)	2016-10-28
ES2988631T3 (es)	2024-11-21
RU2016142896A (ru)	2018-05-07
KR20230012658A (ko)	2023-01-26
HRP20240874T1 (hr)	2024-10-11
US20190388471A1 (en)	2019-12-26
IL247204B (en)	2021-02-28
EP4406610A3 (en)	2024-10-30
IL247204A0 (en)	2016-09-29
AU2022200288A1 (en)	2022-02-10
MX2022010623A (es)	2022-10-07
BR112016022798A2 (pt)	2017-10-17
TWI753848B (zh)	2022-02-01
WO2015157252A1 (en)	2015-10-15
KR20240042250A (ko)	2024-04-01
HRP20211055T1 (hr)	2021-10-01
JP6765966B2 (ja)	2020-10-07
ZA201605657B (en)	2023-10-25
EP3888674B1 (en)	2024-04-03
MY191608A (en)	2022-07-01
MX2016013239A (es)	2017-05-03
AU2015244039A1 (en)	2016-09-15
HUE054588T2 (hu)	2021-09-28
IL280215B (en)	2022-07-01
CA2940671A1 (en)	2015-10-15
RU2016142896A3 (ko)	2019-01-25
PT3129470T (pt)	2021-07-13
KR102651707B1 (ko)	2024-03-29
SI3129470T1 (sl)	2021-08-31
RU2020110834A (ru)	2020-04-27
DK3129470T3 (da)	2021-07-05
PT3888674T (pt)	2024-07-09
PL3888674T3 (pl)	2024-09-23
EP4406610A2 (en)	2024-07-31
RU2718542C2 (ru)	2020-04-08
US10357514B2 (en)	2019-07-23
EP3888674A1 (en)	2021-10-06
FI3888674T3 (fi)	2024-07-02
LT3888674T (lt)	2024-07-25
IL293603A (en)	2022-08-01
EP3129470A1 (en)	2017-02-15
MX395149B (es)	2025-03-24
IL293603B2 (en)	2024-03-01

Publication	Publication Date	Title
IL280215A (en)	2021-03-01	Treatment of cancer using anti-cd19 chimeric antigen receptor
IL250043B (en)	2021-06-30	Chimeric anti–bcma humanized antigen receptor cancer therapy
IL265755A (en)	2019-06-30	A chimeric antibody receptor for cancer therapy
IL250138B (en)	2021-01-31	Cancer treatment using chimeric cd33 receptor antigen
IL241261B (en)	2020-02-27	Cancer treatment using human receptor chimeric anti-cd19 antigen
IL250161A0 (en)	2017-03-30	Ror1-specific chimeric antigen receptors (ntrkr1) for cancer immunotherapy
IL250116A0 (en)	2017-03-30	Cancer treatment using a chimeric receptor for the cll-1 antigen
IL247917A0 (en)	2016-11-30	CD33-specific chimeric antigen receptors for cancer immunotherapy
IL250339A0 (en)	2017-03-30	Egfrviii-specific chimeric antigen receptors for use in cancer immunotherapy
SG11201505896YA (en)	2015-09-29	Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
SG11201606790XA (en)	2016-09-29	Chimeric antigen receptor
IL246540A0 (en)	2016-08-31	Freezeald receptor antibodies for cancer treatment
HK40107394A (en)	2024-10-18	Treatment of cancer using anti-cd19 chimeric antigen receptor
HK1240596A1 (en)	2018-05-25	Treatment of cancer using gfr alpha-4 chimeric antigen receptor
GB201409761D0 (en)	2014-07-16	Chimeric antigen receptor
GB201403481D0 (en)	2014-04-16	Chimeric antigen receptor